With cybercrime costs projected to reach $10.5 trillion annually by 2025, the pharmaceutical supply chain, rich in intellectual property (IP), faces escalating risks that demand robust security measures. In response to these growing threats, resilience within the...
The pharmaceutical industry is under immense pressure. The cost to develop a new drug now tops a staggering $2 billion, and the process can take a decade or longer. Enter real-world data (RWD), information gleaned from patients in their everyday lives. RWD...
As the pharmaceutical industry continues to grow and evolve, so does the amount of unstructured data that companies must navigate. Pharmaceutical companies accumulate vast amounts of data each year, spanning all stages of research and development. With clinical...
Drug development is fraught with challenges, as evidenced by the high rate of candidate failures during clinical trials due to inadequate evidence or ambiguous data. However, the landscape is shifting with the rise of collaborative data initiatives. These initiatives...
During the pandemic, AI swiftly repurposed drugs like baricitinib for COVID-19, saving time and ensuring rapid treatment access. AI predicts compound interactions, reducing drug discovery timelines and costs significantly. Despite its success within some...
